TABLE 2.

Complications post-HSCT and risk for CMV infection post-HSCT

Variables	All patients	Subset at risk for CMV, R(+), and R(x), with CMV post-HSCT	Subset at risk for CMV, R(+), and R(x), without CMV post-HSCT	P-value
N	90	18	62
Acute GVHD
100-day CI of grade II-IV	20 (18%)	3 (17%)	12 (20%)	.42
100-day CI of grade III-IV	7 (8%)	1 (6%)	6 (10%)
aGVHD, median days after (IQR)	22 (15–63)	20 (16–34)	25 (13.5–105)	.82
Chronic GVHD
5-year CI of any cGVHD	5 (22%)	1 (6%)	4 (22%)	.89
5-year CI of severe cGVHD	3 (20%)	0 (0%)	3 (21%)
cGVHD, median days after (IQR)	75 (50–203)	48 (48–48)†	187 (169–1426.5)	.16
Use of Systemic Steroids	40 (44%)	12 (67%)	23 (37%)	.026
Graft Failure
None	71 (79%)	14 (78%)	47 (76%)	.98
Primary	5 (6%)	1 (6%)	4 (6%)
Secondary	14 (16%)	3 (17%)	11 (18%)

Note: Complications post-HSCT and outcome: overall column with characteristics of all 90 patients; univariate analysis performed only for subset of recipients at risk of CMV infection, R(+) and R(x).

Abbreviations: aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; CI, cumulative incidence; CMV, cy tomegalovirus; GVHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplant; IQR, interquar tile range.

^†This patient developed an atypical cGVHD at 48 days after the transplant, affecting skin, eyes, mouth, and vaginal mucosa.